Amgen Inc. (LON:0R0T)
272.50
0.00 (0.00%)
At close: May 9, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Prolia | 4.47B |
Log In |
Log In |
Log In |
Log In |
Prolia Growth | 8.59% |
Log In |
Log In |
Log In |
Log In |
ENBREL | 3.26B |
Log In |
Log In |
Log In |
Log In |
ENBREL Growth | -11.56% |
Log In |
Log In |
Log In |
Log In |
XGEVA | 2.23B |
Log In |
Log In |
Log In |
Log In |
XGEVA Growth | 4.35% |
Log In |
Log In |
Log In |
Log In |
Nplate | 1.45B |
Log In |
Log In |
Log In |
Log In |
Nplate Growth | 1.40% |
Log In |
Log In |
Log In |
Log In |
Aranesp | 1.33B |
Log In |
Log In |
Log In |
Log In |
Aranesp Growth | -1.70% |
Log In |
Log In |
Log In |
Log In |
Other Products | 5.90B |
Log In |
Log In |
Log In |
Log In |
Other Products Growth | 20.56% |
Log In |
Log In |
Log In |
Log In |
Product | 32.78B |
Log In |
Log In |
Log In |
Log In |
Product Growth | 16.32% |
Log In |
Log In |
Log In |
Log In |
Other | 1.35B |
Log In |
Log In |
Log In |
Log In |
Other Growth | -0.37% |
Log In |
Log In |
Log In |
Log In |
KYPROLIS | 1.45B |
Log In |
Log In |
Log In |
Log In |
KYPROLIS Growth | 2.11% |
Log In |
Log In |
Log In |
Log In |
Repatha | 2.36B |
Log In |
Log In |
Log In |
Log In |
Repatha Growth | 33.84% |
Log In |
Log In |
Log In |
Log In |
Otezla | 2.17B |
Log In |
Log In |
Log In |
Log In |
Otezla Growth | -0.96% |
Log In |
Log In |
Log In |
Log In |
EVENITY | 1.66B |
Log In |
Log In |
Log In |
Log In |
EVENITY Growth | 33.25% |
Log In |
Log In |
Log In |
Log In |
BLINCYTO | 1.34B |
Log In |
Log In |
Log In |
Log In |
BLINCYTO Growth | 47.31% |
Log In |
Log In |
Log In |
Log In |
Vectibix | 1.07B |
Log In |
Log In |
Log In |
Log In |
Vectibix Growth | 6.71% |
Log In |
Log In |
Log In |
Log In |
TEZSPIRE | 1.08B |
Log In |
Log In |
Log In |
Log In |
TEZSPIRE Growth | 68.32% |
Log In |
Log In |
Log In |
Log In |
TEPEZZA | 1.81B |
Log In |
Log In |
Log In |
Log In |
TEPEZZA Growth | - |
Log In |
Log In |
Log In |
Log In |
KRYSTEXXA | 1.19B |
Log In |
Log In |
Log In |
Log In |
KRYSTEXXA Growth | - |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
U.S. |
Log In |
Log In |
Log In |
Log In |
U.S. Growth |
Log In |
Log In |
Log In |
Log In |
Rest of World (ROW) |
Log In |
Log In |
Log In |
Log In |
Rest of World (ROW) Growth |
Log In |
Log In |
Log In |
Log In |
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
McKesson Corporation Revenue |
Log In |
Log In |
Log In |
Log In |
McKesson Corporation Revenue Growth |
Log In |
Log In |
Log In |
Log In |
Cencora, Inc. (formerly Amerisource Bergen Corporation) Revenue |
Log In |
Log In |
Log In |
Log In |
Cencora, Inc. (formerly Amerisource Bergen Corporation) Revenue Growth |
Log In |
Log In |
Log In |
Log In |
Cardinal Health, Inc. Revenue |
Log In |
Log In |
Log In |
Log In |
Cardinal Health, Inc. Revenue Growth |
Log In |
Log In |
Log In |
Log In |